1560643-65-3

Upstream product

• 542-92-7 cyclopenta-1,3-diene 
• 16144-91-5 1,2,3,4-tetrahydro-1,4-methanonaphthalene-5,8-diol 
• 3090-47-9 p-dihydroxybenzonorbornadiene 
• 54353-48-9 1,4,4a,8a-tetrahydro-1,4-methanonaphthalene-5,8-dione 
• 106-51-4 p-benzoquinone 
• 1307310-41-3 C₂₅H₃₆BN₃O₄ 
• 1401068-73-2 C₁₃H₁₀F₆O₆S₂ 
• 1250939-45-7 C₁₉H₂₄BrN₃O₂ 
• 1250939-42-4 (2-(2-(4-bromophenyl)-2-oxoethyl)) 1-(tert-butyl) (2S,4S)-4-methylpyrrolidine-1,2-dicarboxylate 
• 364750-81-2 N-tert-Butyloxycarbonyl-(2S,4S)-4-methylproline 

Downstream Products

• 1560643-76-6 C₄₃H₅₄N₆O₄ 
• 1560639-00-0 C₄₇H₆₀N₈O₆ 
• 1560643-67-5 C₃₆H₄₆BN₃O₄ 

Relevant academic research and scientific papers

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or harmaceutical com ositions thereof in the treatment of HCV infection or he atitis C.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.